SMS PHARMACEUTICALS LTD.
Latest filings
- SMS Pharmaceuticals posts investor conference call audio · Investor Communications
- Newspaper publication of September 2026 financial results · Compliance
- Q2 FY27 profit rises 57% as revenue grows 30% · Compliance
Snapshot
What the business is, and whether it's a good one at a fair price.
Manufactures active pharmaceutical ingredients (APIs) — the bulk drug substances used by generic drug makers — across therapeutic areas including anti-inflammatory (ibuprofen is a major product), anti-retroviral (ARV), anti-erectile dysfunction, and anti-diabetic (the last is being wound down). Backward integration into ibuprofen raw materials, built over three years, is the main margin lever; FY26 EBITDA margin reached 20% on revenue of INR886.87 crore with materials at 58.2% of revenue. A brownfield expansion is under way, intended to add new capacity by March 2027 and bring new high-margin APIs on stream from FY28. The company files DMFs and CEPs to access regulated export markets and is shifting its mix toward higher-value APIs over time. A new peptides subsidiary (SMS Peptides) and a CDMO initiative are medium-term options, not yet material to revenue. Customer base is concentrated: the single largest customer accounts for 28% of FY26 revenue.
Scorecard
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Strengths
Nothing stands out in the filed numbers.Concerns
Charts
How has the market priced it — with filings on the timeline?
SMSPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from SMS PHARMACEUTICALS LTD.'s filed financials and exchange disclosures
What does SMS PHARMACEUTICALS LTD. do?
SMS PHARMACEUTICALS LTD. is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol SMSPHARMA.
Is SMS PHARMACEUTICALS LTD. profitable?
Yes. Over the trailing twelve months SMS PHARMACEUTICALS LTD. reported a net profit of ₹102 Cr on revenue of ₹898 Cr.
Does SMS PHARMACEUTICALS LTD. pay a dividend?
Yes. The dividend yield is 0.08% at the current price. It paid out 4% of its profit as dividend in FY26.
Is SMS PHARMACEUTICALS LTD. debt-free?
No. It reported borrowings of ₹365 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹319 Cr after cash. Debt stands at 0.46× equity. That is higher than 81% of its 166 Pharmaceuticals peers.
Is SMS PHARMACEUTICALS LTD. expensive compared with its peers?
On trailing P/E, SMS PHARMACEUTICALS LTD. ranks 114 of 160 in Pharmaceuticals — cheaper than 29% of them, against an industry median of 29.3×. This is a position, not a valuation judgement.
How much does the SMS PHARMACEUTICALS LTD. share price move in a day?
On a typical session SMS PHARMACEUTICALS LTD. moves 1.33% — that is the median absolute close-to-close move across its last 268 trading days. MarketPing measures each filing's price reaction against it.
Where can I track SMS PHARMACEUTICALS LTD.'s announcements?
Every NSE and BSE filing by SMS PHARMACEUTICALS LTD. appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.